InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present ONP-002 Concussion Program at IPAC-RS 2026 Nasal Innovation Forum

Oragenics (NYSE American: OGEN) announced that Chief Medical Officer James P. Kelly, MD, is scheduled to present at the IPAC-RS 2026 Nasal Innovation Forum on Sept. 17 in Jersey City, New Jersey. Kelly’s presentation is expected to focus on the development and clinical translation of ONP-002, the company’s first-in-class intranasal neurosteroid candidate for concussion, including its proposed mechanism of action and Oragenics’ proprietary breath-powered intranasal delivery device designed to deliver the drug to the brain while minimizing systemic exposure.

Kelly is also expected to discuss Oragenics’ ongoing Phase IIa feasibility trial, which is enrolling at three sites in Australia, as well as the clinical framework for anticipated U.S. development. Oragenics is advancing an Investigational New Drug application for ONP-002, with submission anticipated in the fourth quarter of 2026. Phase I single and multiple ascending-dose trials have been completed with a favorable safety and tolerability profile, and there are currently no FDA-approved pharmacological treatments for mild traumatic brain injury, or concussion.

To view the full press release, visit https://ibn.fm/eDK9T

About Oragenics, Inc.

Oragenics, Inc. is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The Company is working on advancing its lead candidate, ONP-002, as a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics is working on commencing clinical trials in Australia for ONP-002 , with U.S. Phase 2b trials planned to follow. The Company’s intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders. Oragenics is committed to developing innovative therapies that address significant unmet medical needs in neurological care. For more information, visit oragenics.com.

NOTE TO INVESTORS: The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present ONP-002 Concussion Program at IPAC-RS 2026 Nasal Innovation Forum.